"Le CH de Troyes propose la majorité des disciplines médicales, chirurgicales et médico-techniques. Il possède notamment une maternité de niveau 3 (niveau maximal signifiant qu’elle dispose d’une unité d’obstétrique, d’une unité de néonatologie et d’une unité de réanimation néonatale), un service d’urgences/SMUR et un plateau technique performant : deux IRM, deux scanners, deux mammographes, dix salles de bloc opératoire, deux accélérateurs de particules (radiothérapie), un TepScan… Des unités innovantes complètent son offre de soins telles qu’une unité neurovasculaire aiguë permettant la prise en charge des accidents vasculaires cérébraux (AVC), une unité de génétique et des unités de soins critiques."

During the past decade, CH Troyes conducted 31 clinical trials. In the 10-year time frame, 31 clinical trials started and 1 clinical trials were completed, i.e. on average, 3.2% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 1 clinical trials were completed. i.e. 5.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CH Troyes" #1 sponsor was "Intergroupe Francophone de Cancerologie Thoracique" with 4 trials, followed by "Centre Hospitalier Universitaire Dijon" with 3 trials sponsored, "The Lymphoma Academic Research Organisation" with 3 trials sponsored, "Central Hospital, Nancy, France" with 2 trials sponsored and "Centre Hospitalier of Chartres" with 2 trials sponsored. Other sponsors include 27 different institutions and companies that sponsored additional 33 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CH Troyes" #1 collaborator was "AstraZeneca" with 2 trials as a collaborator, "Central Hospital, Nancy, France" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Acute Leukemia French Association" with 1 trials as a collaborator and "Association Clinique Thérapeutique Infantile du val de Marne" with 1 trials as a collaborator. Other collaborators include 31 different institutions and companies that were collaborators in the rest 41 trials.

According to Clinical.Site data, the most researched conditions in "CH Troyes" are "Atrial Fibrillation" (2 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Critical Illness" (2 trials), "Psoriatic Arthritis" (2 trials) and "Rheumatoid Arthritis" (2 trials). Many other conditions were trialed in "CH Troyes" in a lesser frequency.

Most popular intervention types in "CH Troyes" are "Drug" (18 trials), "Other" (17 trials), "Procedure" (2 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Administration of the IPREA3 questionnaire" (2 trials), "Immediate feedback through electronic reminder messages" (2 trials), "Targeted interventions in each ICU to reduce discomforts" (2 trials) and "1 year follow-up to assess psychiatric morbidity" (1 trials). Other intervention names were less common.

The vast majority of trials in "CH Troyes" are 43 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "CH Troyes". undefined are not yet recruiting, 9 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in CH Troyes, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in CH Troyes, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 10 trials that are defined as “Not Applicable".